A New Dawn in the Management of Idiopathic Hypersomnia: An Adaptive Learning Approach to Diagnosis and Implementing Clinical Trial Updates
Adaptive LearningPremiere Date: Wednesday, January 18, 2023
This activity offers CE credit for:%>
- ABIM (MOC)
- Medicine (accme)
- Nursing (ANCC)
- Pharmacy (acpe)
- PA (aapa)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, January 18, 2024
|Nancy R. Foldvary-Schaefer, DO, MS, FAASM, FAAN, FAES, FACNS
Professor of Neurology
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Director, Cleveland Clinic Sleep Disorders Center
Idiopathic hypersomnia (IH) is a chronic, debilitating sleep disorder mainly characterized by excessive daytime sleepiness (EDS) as well as prolonged nocturnal sleep and/or daytime naps, unrefreshing sleep, sleep inertia, and autonomic dysfunction. These symptoms, in turn, often result in diminished psychosocial functioning, cognitive dysfunction, school/work performance, and quality of life (QoL), subsequently impacting family, friends, and work colleagues, as well as public health and safety. Contributing to the debilitation caused by IH is the failure of health care practitioners (HCPs) to accurately diagnose IH in a timely manner. In fact, an accurate diagnosis can often take years, leaving patients with IH struggling with personal, work, and psychosocial dysfunction in the interim.
While advances in sleep medicine have resulted in the first and only FDA-approved therapy for IH, incorporating this therapy into practice and monitoring treatment efficacy requires best practices. Please join Dr. Foldvary-Schaefer in this adaptive learning activity for a personalized journey through the latest clinical evidence for IH, strategies to transition patients to new therapies, and evidence-based tools to assess symptom severity and treatment effectiveness.
At the end of this CE activity, participants should be able to:
- Recognize the burden of IH.
- Utilize validated tools to measure the impact of IH on function and QoL.
- Assess the efficacy and safety data for novel agents to manage IH.
Supported by an educational grant from Jazz Pharmaceuticals, Inc.
Sleep specialists, pulmonologists, psychiatrists, neurologists, primary care providers, PAs, nurse practitioners, nurses, and pharmacists.
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Royal College MOC:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
MIPS Improvement Activity:
This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Dr. Foldvary-Schaefer reports the following financial relationships:
Advisory Board: Jazz Pharmaceuticals, Inc. (Publication Committee)
Research Support: Jazz Pharmaceuticals, Inc.; Suven Pharmaceuticals Limited; Takeda Pharmaceuticals U.S.A., Inc.; and Vanda Pharmaceuticals
The following Peer Reviewer and CME Outfitters staff reports no financial relationships:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).